Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks best approaches for returning abdominal sarcoma

NCT ID NCT07377747

Disease control Sponsor: Australia and New Zealand Sarcoma Association Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This study follows 100 adults whose retroperitoneal liposarcoma has returned after initial surgery. Researchers will compare outcomes of surgery alone versus radiation and/or chemotherapy before surgery. The goal is to improve treatment decisions and validate a prediction tool for this rare cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Dec 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients diagnosed with localized, resectable recurrent retroperitoneal liposarcoma attending and having treatment at the study site.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult age ≥ 18 presenting with first recurrent well-differentiated and/or dedifferentiated liposarcoma of retroperitoneal space or pelvis after previous macroscopically complete resection (R0/R1 resection) 2. No distant metastasis on cross-sectional imaging of chest/abdomen/pelvis (CT and/or MRI) within 1 month to confirm the absence of metastatic disease 3. Previous histologically proven well-differentiated or dedifferentiated liposarcoma histology only 4. Sarcoma not originating from bone or abdominal or gynecological viscera 5. Tumor confirmed to be resectable with likely R0/R1 resection, and all disease must be deemed to be treatable by RT (joint decision by surgeon and radiation oncologist at a sarcoma multidisciplinary team meeting) 6. WHO performance status 0-2 7. American Society of Anaesthesiologist (ASA) score 1-3 8. No prior RT for the retroperitoneal liposarcoma 9. Prior systemic therapy is allowed 10. No concurrent active malignancy (except for low risk skin malignancy, low risk prostate carcinoma, low risk breast carcinoma including in situ disease) 11. Women of childbearing potential must have a negative pregnancy test within 3 weeks prior to the first day of study treatment 12. Patient deemed able to comply with study requirements according to investigator evaluation 13. Signed, IRB-approved written informed consent Exclusion Criteria: 1. Unresectable disease or likely R2 resection as assessed by the multidisciplinary sarcoma team 2. Extent of recurrence where preoperative RT to all visible disease is not deemed to be feasible 3. Contradiction for RT such as history of bowel obstruction or mesenteric ischemia or severe chronic inflammatory bowel disease 4. Myxoid liposarcoma histology 5. Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Retroperitoneal liposarcoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

liposarcoma Retroperitoneal liposarcoma retroperitoneal sarcoma sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Retroperitoneal liposarcoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    13 sites in 8 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • A.C.Camargo Cancer Center - Fundacao Antonio Prudente

    RECRUITING

    Liberdade, São Paulo, 01509-010, Brazil

  • Brigham and Women's Hospital

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02115, United States

  • Chris O'Brien Lifehouse

    RECRUITING

    Camperdown, New South Wales, 2050, Australia

  • Emory Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Institut Curie Hospital

    RECRUITING

    Paris, 75005, France

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Maria Sklodowska-Curie National Research Institute of Oncology

    NOT_YET_RECRUITING

    Warsaw, 00-001, Poland

  • OSU James Hospital

    RECRUITING

    Columbus, Ohio, 43210, United States

  • Peter MacCallum Cancer Centre

    RECRUITING

    Melbourne, Victoria, 3000, Australia

    Contact Email: •••••@•••••

  • Prince of Wales Hospital

    RECRUITING

    Randwick, New South Wales, 2031, Australia

  • The Netherlands Cancer Institute

    RECRUITING

    Amsterdam, North Holland, 1066 CX, Netherlands

  • The Princess Margaret Cancer Centre

    RECRUITING

    Toronto, Ontario, M5G 2C4, Canada

  • UZ Leuven

    RECRUITING

    Leuven, Flemish Brabant, 3000, Belgium